A component of factor VIII preparations which can be separated from factor VIII activity down modulates human monocyte functions.
In this study we investigated different aspects of monocyte functions following interaction of monocytes (Mo) with therapeutic concentrations of factor VIII (F VIII) concentrate. A short (one-hour) treatment of normal Mo with F VIII concentrates led to a significant (P less than 0.001) down modulation of Fc receptors expressed in the Mo plasma membrane. This down modulation was accompanied by a decrease of Mo effector functions that was expressed by a reduced capacity of F VIII-treated Mo to release O2 radicals (40% of controls) and to kill bacteria (% killing: control Mo, 65%; F VIII-treated Mo, 24% to 51%). Further studies showed that the modulating activity was due to a contaminant present in F VIII concentrates (immune complexes or IgG aggregates). Fractionation using molecular sieving revealed that the modulatory activity was confined to a high-molecular range fraction (Mr greater than 1,270,000 daltons), while the fraction containing monomeric IgG had no effect. Further fractionation by affinity chromatography on protein A-Sepharose separated the coagulation activity (effluent) from the Mo function-modulating activity (eluate). We conclude that treatment with F VIII concentrates might contribute to an immunocompromised state in some hemophiliacs and facilitate opportunistic infections in these patients.
D000936:Antigen-Antibody Complex; D001770:Blood Bactericidal Activity / Q000187:drug effects; D005169:Factor VIII / Q000009:adverse effects / Q000032:analysis* / Q000276:immunology; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D008163:Luminescent Measurements; D046911:Macromolecular Substances; D008970:Molecular Weight; D009000:Monocytes / Q000187:drug effects*; D011961:Receptors, Fc / Q000378:metabolism; D013481:Superoxides / Q000378:metabolism
D000936:Antigen-Antibody Complex; D046911:Macromolecular Substances; D011961:Receptors, Fc; D013481:Superoxides; D005169:Factor VIII